Pricing
  1. JP-listed companies
  2. Carna Biosciences, Inc.
  3. Financials
  4. Earnings per share

Carna Biosciences, Inc. (4572)

Market cap
¥7.4B
P/E ratio
-3.5x
Karna Bioscience develops kinase inhibitor drugs and provides drug discovery support services to pharmaceutical companies and research institutions.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndEarnings per share (JPY)YoY (%)
Dec 31, 2025-113.6-6.59%
Dec 31, 2024-121.6+77.27%
Dec 31, 2023-68.6-30.76%
Dec 31, 2022-99.1+135.39%
Dec 31, 2021-42.1-53.39%
Dec 31, 2020-90.3-218.78%
Dec 31, 201976.1-160.83%
Dec 31, 2018-125+59.20%
Dec 31, 2017-78.5+148.20%
Dec 31, 2016-31.6-160.14%
Dec 31, 201552.6-151.49%
Dec 31, 2014-102.2+179.26%
Dec 31, 2013-36.6-50.07%
Dec 31, 2012-73.3+18.96%
Dec 31, 2011-61.6

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat